Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 19;5(1):100.
doi: 10.1038/s41392-020-0211-1.

Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients

Zhi-Sheng Xu #  1   2 , Ting Shu #  3 , Liang Kang #  4 , Di Wu #  3 , Xing Zhou #  4 , Bo-Wei Liao  1 , Xiu-Lian Sun  1 , Xi Zhou  3 , Yan-Yi Wang  5   6
Affiliations

Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients

Zhi-Sheng Xu et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Levels of CCGFs increased in COVID-19 patients. a Levels of CCGFs that were increased in COVID-19 patients but not correlated to disease severity. b Levels of CCGFs that were increased in COVID-19 patients and positively correlated to COVID-19 disease severity. c Levels of CCGFs that were increased in COVID-19 patients and negatively correlated to COVID-19 disease severity. Dynamic levels of the indicated CCGFs in plasma samples of mild (n = 10), severe (n = 7), and fatal (n = 6) COVID-19 patients at the indicated days after diagnosis as well as healthy individuals (n = 4) were measured by Bio-plex. Data shown are averages plus SD of the CCGF levels in mild, severe, and fatal COVID-19 patients, and averages of the CCGF levels in healthy individuals (dotted line). *p < 0.05; **p < 0.01 (Turkey’s test as described in Supplementary Information)
See this image and copyright information in PMC

References

    1. Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. Tay MZ, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 2020;20:363–374. doi: 10.1038/s41577-020-0311-8. - DOI - PMC - PubMed
    1. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treatment options. Clin. Immunol. 2020;215:108448. doi: 10.1016/j.clim.2020.108448. - DOI - PMC - PubMed
    1. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–474. doi: 10.1126/science.abb8925. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources